The first healthy volunteer has been dosed in a Phase 1 trial testing ZMA001, Zymedi’s first-in-class investigational therapy for pulmonary arterial hypertension (PAH). The trial (NCT05967299), still recruiting participants at a clinical center in Bethesda, Maryland, will evaluate the safety, tolerability, and pharmacological properties of ZMA001.
News
Access to pulmonary rehabilitation programs for people with pulmonary hypertension (PH) and other chronic respiratory conditions is considerably more difficult for those living in rural U.S. regions than in urban areas, scientists report. Travel longer than 60 minutes affects more than 14 million U.S. residents of rural or underpopulated…
A Phase 3 trial of an oral formulation of levosimendan, dubbed TNX-103, in people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), has enrolled the first participant. LEVEL (NCT05983250) is recruiting up to 152 adults with PH-HFpEF, ages 18-85,…
An inflammatory protein called CIRP may serve as a marker of pulmonary hypertension (PH) in people with chronic obstructive pulmonary disease (COPD), a chronic inflammatory disease of the lungs, a new study shows. “Our study reveals elevated expression of [extracellular] CIRP in the lung tissue and [blood] of…
An investigational fixed-dose combination of macitentan and tadalafil in a single tablet (M/T STCT) led to improvements in blood flow and reductions in a biomarker of heart failure for people with pulmonary arterial hypertension (PAH) who were treatment naïve or previously received monotherapies, according to final…
Echocardiogram (ECG) measures that indicate the heart’s right ventricle (RV) and the pulmonary arteries are working poorly together to send blood to the lungs may help predict the presence of pulmonary hypertension (PH) in people with a certain type of heart failure, a recent publication indicates.
The U.S. Food and Drug Administration (FDA) has approved Cereno Scientific’s investigational drug CS1 in an extension of the ongoing Phase 2 clinical trial testing it in people with pulmonary arterial hypertension (PAH). This expanded access is sometimes called compassionate use. The…
A variant in the gene encoding the ALDH2 enzyme — fully known as aldehyde dehydrogenase 2 — was linked to an increased risk of pulmonary hypertension due to left heart disease (PH-LHD) among heart failure patients, a study in China found. Also called a polymorphism, meaning it involves one…
Note: This story was updated Jan. 30, 2024, to correct the approved indications of available treprostinil formulations. The U.S. Food and Drug Administration (FDA) has delayed its decision to extend the use of Yutrepia — Liquidia‘s inhaled dry powder formulation of treprostinil — to people with…
A protein known as MCJ might be a target of treatments needed to preserve heart function in people with pulmonary hypertension (PH), a study reports. Elevated levels of MCJ were found in the lung tissue of individuals affected by the low oxygen conditions of chronic obstructive pulmonary disease…
After a diagnosis of pulmonary arterial hypertension (PAH), rapidly starting treatment with a combination of therapies — both an endothelin receptor antagonist (ERA) and a phosphodiesterase type 5 inhibitor (PDE5i) — can lead to notable short-term improvements in heart health and physical function. That’s according to a new…
In people with pulmonary hypertension (PH), the endothelial cells that line the inside of blood vessels in the lungs take on features that are similar to what’s seen in some cancers, a new study found. The researchers who uncovered these features in these hard-to-access cells noted that they may…
